| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Subject Id | Phase | Age (Years) | Sex | Cohort | Randomization Datetime | Dose 1 Datetime | Dose 2 Datetime | Visit Name | Visit Day | Visit Datetime | Test | AVisit | AVisitNum | Result 1 | Result 2 | Offset (if Result 2) | |||||||||
2 | 10011004 | Phase 1 | 42 | Female | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/4/20 13:00 | 5/4/20 13:00 | 5/26/20 13:00 | V1_DAY1_VAX1_S | 1 | 5/4/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
3 | 10011004 | Phase 1 | 42 | Female | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/4/20 13:00 | 5/4/20 13:00 | 5/26/20 13:00 | V3_WEEK1_POSTVAX1_S | 7 | 5/11/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 1 | 2 | 10 | |||||||||||
4 | 10011004 | Phase 1 | 42 | Female | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/4/20 13:00 | 5/4/20 13:00 | 5/26/20 13:00 | V4_WEEK3_VAX2_S | 21 | 5/26/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 10 | |||||||||||
5 | 10011004 | Phase 1 | 42 | Female | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/4/20 13:00 | 5/4/20 13:00 | 5/26/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 6/2/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 87,86881415 | |||||||||||
6 | 10011004 | Phase 1 | 42 | Female | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/4/20 13:00 | 5/4/20 13:00 | 5/26/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 6/9/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 101,6595396 | |||||||||||
7 | 10011004 | Phase 1 | 42 | Female | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/4/20 13:00 | 5/4/20 13:00 | 5/26/20 13:00 | V7_MONTH1_S | 49 | 6/29/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 52,58656863 | |||||||||||
8 | 10011006 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V1_DAY1_VAX1_S | 1 | 5/6/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
9 | 10011006 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V3_WEEK1_POSTVAX1_S | 7 | 5/13/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 1 | 2 | 10 | |||||||||||
10 | 10011006 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V4_WEEK3_VAX2_S | 21 | 5/27/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 10 | |||||||||||
11 | 10011006 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 6/2/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 222,447387 | |||||||||||
12 | 10011006 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 6/9/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 303,8986673 | |||||||||||
13 | 10011006 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V7_MONTH1_S | 49 | 6/24/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 127,364634 | |||||||||||
14 | 10011007 | Phase 1 | 24 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/28/20 13:00 | V1_DAY1_VAX1_S | 1 | 5/6/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
15 | 10011007 | Phase 1 | 24 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/28/20 13:00 | V3_WEEK1_POSTVAX1_S | 7 | 5/14/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 1 | 2 | 10 | |||||||||||
16 | 10011007 | Phase 1 | 24 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/28/20 13:00 | V4_WEEK3_VAX2_S | 21 | 5/28/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 10 | |||||||||||
17 | 10011007 | Phase 1 | 24 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/28/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 6/3/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 194,9307569 | |||||||||||
18 | 10011007 | Phase 1 | 24 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/28/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 6/9/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 402,4883849 | |||||||||||
19 | 10011007 | Phase 1 | 24 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/28/20 13:00 | V7_MONTH1_S | 49 | 6/25/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 118,7052231 | |||||||||||
20 | 10011008 | Phase 1 | 27 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V1_DAY1_VAX1_S | 1 | 5/6/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
21 | 10011008 | Phase 1 | 27 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V3_WEEK1_POSTVAX1_S | 7 | 5/13/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 1 | 2 | 10 | |||||||||||
22 | 10011008 | Phase 1 | 27 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V4_WEEK3_VAX2_S | 21 | 5/27/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 10 | |||||||||||
23 | 10011008 | Phase 1 | 27 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 6/3/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 167,3388479 | |||||||||||
24 | 10011008 | Phase 1 | 27 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 6/8/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 149,6455813 | |||||||||||
25 | 10011008 | Phase 1 | 27 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V7_MONTH1_S | 49 | 6/25/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 64,99016772 | |||||||||||
26 | 10011009 | Phase 1 | 40 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V1_DAY1_VAX1_S | 1 | 5/6/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
27 | 10011009 | Phase 1 | 40 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V3_WEEK1_POSTVAX1_S | 7 | 5/13/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 1 | 2 | 10 | |||||||||||
28 | 10011009 | Phase 1 | 40 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V4_WEEK3_VAX2_S | 21 | 5/27/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 23,20429271 | |||||||||||
29 | 10011009 | Phase 1 | 40 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 6/2/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 311,436992 | |||||||||||
30 | 10011009 | Phase 1 | 40 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 6/9/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 437,3274288 | |||||||||||
31 | 10011009 | Phase 1 | 40 | Male | Stage 1, Age 18 to 55, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 5/6/20 13:00 | 5/6/20 13:00 | 5/27/20 13:00 | V7_MONTH1_S | 49 | 6/30/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 189,6863727 | |||||||||||
32 | 10011011 | Phase 1 | 32 | Female | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/11/20 13:00 | 5/11/20 13:00 | 6/1/20 13:00 | V1_DAY1_VAX1_S | 1 | 5/11/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
33 | 10011011 | Phase 1 | 32 | Female | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/11/20 13:00 | 5/11/20 13:00 | 6/1/20 13:00 | V3_WEEK1_POSTVAX1_S | 7 | 5/18/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 1 | 2 | 10 | |||||||||||
34 | 10011011 | Phase 1 | 32 | Female | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/11/20 13:00 | 5/11/20 13:00 | 6/1/20 13:00 | V4_WEEK3_VAX2_S | 21 | 6/1/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 39,24597049 | |||||||||||
35 | 10011011 | Phase 1 | 32 | Female | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/11/20 13:00 | 5/11/20 13:00 | 6/1/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 6/8/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 590,8879589 | |||||||||||
36 | 10011011 | Phase 1 | 32 | Female | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/11/20 13:00 | 5/11/20 13:00 | 6/1/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 6/15/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 1084,342197 | |||||||||||
37 | 10011011 | Phase 1 | 32 | Female | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/11/20 13:00 | 5/11/20 13:00 | 6/1/20 13:00 | V7_MONTH1_S | 49 | 6/29/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 446,2923257 | |||||||||||
38 | 10011012 | Phase 1 | 50 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V1_DAY1_VAX1_S | 1 | 5/13/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
39 | 10011012 | Phase 1 | 50 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V3_WEEK1_POSTVAX1_S | 7 | 5/19/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 1 | 2 | 10 | |||||||||||
40 | 10011012 | Phase 1 | 50 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V4_WEEK3_VAX2_S | 21 | 6/3/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 20,89957416 | |||||||||||
41 | 10011012 | Phase 1 | 50 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 6/11/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 283,8927614 | |||||||||||
42 | 10011012 | Phase 1 | 50 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 6/16/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 369,8428856 | |||||||||||
43 | 10011012 | Phase 1 | 50 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V7_MONTH1_S | 49 | 7/1/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 154,549539 | |||||||||||
44 | 10011015 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/11/20 13:00 | 5/11/20 13:00 | 6/1/20 13:00 | V1_DAY1_VAX1_S | 1 | 5/11/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
45 | 10011015 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/11/20 13:00 | 5/11/20 13:00 | 6/1/20 13:00 | V3_WEEK1_POSTVAX1_S | 7 | 5/18/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 1 | 2 | 10 | |||||||||||
46 | 10011015 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/11/20 13:00 | 5/11/20 13:00 | 6/1/20 13:00 | V4_WEEK3_VAX2_S | 21 | 6/1/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 150,8517484 | |||||||||||
47 | 10011015 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/11/20 13:00 | 5/11/20 13:00 | 6/1/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 6/8/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 588,4360203 | |||||||||||
48 | 10011015 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/11/20 13:00 | 5/11/20 13:00 | 6/1/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 6/15/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 547,0429599 | |||||||||||
49 | 10011015 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/11/20 13:00 | 5/11/20 13:00 | 6/1/20 13:00 | V7_MONTH1_S | 49 | 6/29/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 326,5082082 | |||||||||||
50 | 10011017 | Phase 1 | 52 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V1_DAY1_VAX1_S | 1 | 5/13/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
51 | 10011017 | Phase 1 | 52 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V3_WEEK1_POSTVAX1_S | 7 | 5/20/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 1 | 2 | 10 | |||||||||||
52 | 10011017 | Phase 1 | 52 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V4_WEEK3_VAX2_S | 21 | 6/3/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 22,75202848 | |||||||||||
53 | 10011017 | Phase 1 | 52 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 6/10/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 196,6876966 | |||||||||||
54 | 10011017 | Phase 1 | 52 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 6/16/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 575,8018062 | |||||||||||
55 | 10011017 | Phase 1 | 52 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V7_MONTH1_S | 49 | 7/2/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 155,3161936 | |||||||||||
56 | 10011019 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V1_DAY1_VAX1_S | 1 | 5/13/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
57 | 10011019 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V3_WEEK1_POSTVAX1_S | 7 | 5/19/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 1 | 2 | 10 | |||||||||||
58 | 10011019 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V4_WEEK3_VAX2_S | 21 | 6/3/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 32,89962918 | |||||||||||
59 | 10011019 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 6/11/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 457,5623127 | |||||||||||
60 | 10011019 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 6/16/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 286,026712 | |||||||||||
61 | 10011019 | Phase 1 | 28 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V7_MONTH1_S | 49 | 7/1/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 90,02757244 | |||||||||||
62 | 10011020 | Phase 1 | 26 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V1_DAY1_VAX1_S | 1 | 5/13/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
63 | 10011020 | Phase 1 | 26 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V3_WEEK1_POSTVAX1_S | 7 | 5/19/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 1 | 2 | 10 | |||||||||||
64 | 10011020 | Phase 1 | 26 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V4_WEEK3_VAX2_S | 21 | 6/3/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 10 | |||||||||||
65 | 10011020 | Phase 1 | 26 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 6/11/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 99,23305901 | |||||||||||
66 | 10011020 | Phase 1 | 26 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 6/16/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 188,1080541 | |||||||||||
67 | 10011020 | Phase 1 | 26 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V7_MONTH1_S | 49 | 7/1/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 26,90912485 | |||||||||||
68 | 10011024 | Phase 1 | 23 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V1_DAY1_VAX1_S | 1 | 5/13/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
69 | 10011024 | Phase 1 | 23 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V3_WEEK1_POSTVAX1_S | 7 | 5/19/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 1 | 2 | 10 | |||||||||||
70 | 10011024 | Phase 1 | 23 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V4_WEEK3_VAX2_S | 21 | 6/3/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 38,51008959 | |||||||||||
71 | 10011024 | Phase 1 | 23 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 6/11/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 649,4505986 | |||||||||||
72 | 10011024 | Phase 1 | 23 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 6/16/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 677,2253982 | |||||||||||
73 | 10011024 | Phase 1 | 23 | Male | Stage 1, Age 18 to 55, Medium dose level (30mcg), 21 Day (BNT162b1 or PBO) | 5/13/20 13:00 | 5/13/20 13:00 | 6/3/20 13:00 | V7_MONTH1_S | 49 | 7/6/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 233,1851196 | |||||||||||
74 | 10011037 | Phase 1 | 66 | Female | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 6/30/20 13:00 | V1_DAY1_VAX1_S | 1 | 6/11/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
75 | 10011037 | Phase 1 | 66 | Female | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 6/30/20 13:00 | V4_WEEK3_VAX2_S | 21 | 6/30/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 10 | |||||||||||
76 | 10011037 | Phase 1 | 66 | Female | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 6/30/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 7/6/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 37,64728676 | |||||||||||
77 | 10011037 | Phase 1 | 66 | Female | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 6/30/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 7/14/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 249,3302027 | |||||||||||
78 | 10011037 | Phase 1 | 66 | Female | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 6/30/20 13:00 | V7_MONTH1_S | 49 | 7/30/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 190,6236082 | |||||||||||
79 | 10011039 | Phase 1 | 69 | Male | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/9/20 13:00 | 6/9/20 13:00 | 6/29/20 13:00 | V1_DAY1_VAX1_S | 1 | 6/9/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
80 | 10011039 | Phase 1 | 69 | Male | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/9/20 13:00 | 6/9/20 13:00 | 6/29/20 13:00 | V4_WEEK3_VAX2_S | 21 | 6/29/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 10 | |||||||||||
81 | 10011039 | Phase 1 | 69 | Male | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/9/20 13:00 | 6/9/20 13:00 | 6/29/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 7/6/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 10 | |||||||||||
82 | 10011039 | Phase 1 | 69 | Male | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/9/20 13:00 | 6/9/20 13:00 | 6/29/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 7/13/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 22,72576511 | |||||||||||
83 | 10011039 | Phase 1 | 69 | Male | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/9/20 13:00 | 6/9/20 13:00 | 6/29/20 13:00 | V7_MONTH1_S | 49 | 7/27/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 10 | |||||||||||
84 | 10011040 | Phase 1 | 65 | Male | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 7/2/20 13:00 | V1_DAY1_VAX1_S | 1 | 6/11/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
85 | 10011040 | Phase 1 | 65 | Male | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 7/2/20 13:00 | V4_WEEK3_VAX2_S | 21 | 7/2/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 34,66646506 | |||||||||||
86 | 10011040 | Phase 1 | 65 | Male | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 7/2/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 7/9/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 116,0567103 | |||||||||||
87 | 10011040 | Phase 1 | 65 | Male | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 7/2/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 7/16/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 122,8495014 | |||||||||||
88 | 10011040 | Phase 1 | 65 | Male | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 7/2/20 13:00 | V7_MONTH1_S | 49 | 7/30/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 107,9042909 | |||||||||||
89 | 10011041 | Phase 1 | 70 | Female | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 7/2/20 13:00 | V1_DAY1_VAX1_S | 1 | 6/11/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
90 | 10011041 | Phase 1 | 70 | Female | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 7/2/20 13:00 | V4_WEEK3_VAX2_S | 21 | 7/2/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 10 | |||||||||||
91 | 10011041 | Phase 1 | 70 | Female | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 7/2/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 7/9/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 22,93241156 | |||||||||||
92 | 10011041 | Phase 1 | 70 | Female | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 7/2/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 7/16/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 20,35984283 | |||||||||||
93 | 10011041 | Phase 1 | 70 | Female | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/11/20 13:00 | 6/11/20 13:00 | 7/2/20 13:00 | V7_MONTH1_S | 49 | 7/31/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 20,77007463 | |||||||||||
94 | 10011043 | Phase 1 | 74 | Female | Stage 1, Age 65 to 85, Low-Mid dose level (20mcg), 21 Day (BNT162b1 or PBO) | 6/15/20 13:00 | 6/15/20 13:00 | 7/8/20 13:00 | V1_DAY1_VAX1_S | 1 | 6/15/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
95 | 10011043 | Phase 1 | 74 | Female | Stage 1, Age 65 to 85, Low-Mid dose level (20mcg), 21 Day (BNT162b1 or PBO) | 6/15/20 13:00 | 6/15/20 13:00 | 7/8/20 13:00 | V4_WEEK3_VAX2_S | 21 | 7/8/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 10 | |||||||||||
96 | 10011043 | Phase 1 | 74 | Female | Stage 1, Age 65 to 85, Low-Mid dose level (20mcg), 21 Day (BNT162b1 or PBO) | 6/15/20 13:00 | 6/15/20 13:00 | 7/8/20 13:00 | V5_WEEK1_POSTVAX2_S | 28 | 7/14/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Week after Vaccination 2 | 4 | 204,5489184 | |||||||||||
97 | 10011043 | Phase 1 | 74 | Female | Stage 1, Age 65 to 85, Low-Mid dose level (20mcg), 21 Day (BNT162b1 or PBO) | 6/15/20 13:00 | 6/15/20 13:00 | 7/8/20 13:00 | V6_WEEK2_POSTVAX2_S | 35 | 7/20/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 2 Weeks after Vaccination 2 | 5 | 64,93291538 | |||||||||||
98 | 10011043 | Phase 1 | 74 | Female | Stage 1, Age 65 to 85, Low-Mid dose level (20mcg), 21 Day (BNT162b1 or PBO) | 6/15/20 13:00 | 6/15/20 13:00 | 7/8/20 13:00 | V7_MONTH1_S | 49 | 8/12/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 1 Month after Vaccination 2 | 6 | 133,5129956 | |||||||||||
99 | 10011044 | Phase 1 | 79 | Male | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/9/20 13:00 | 6/9/20 13:00 | 6/29/20 13:00 | V1_DAY1_VAX1_S | 1 | 6/9/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | Before Vaccination 1 | 1 | 10 | |||||||||||
100 | 10011044 | Phase 1 | 79 | Male | Stage 1, Age 65 to 85, Low dose level (10mcg), 21 Day (BNT162b1 or PBO) | 6/9/20 13:00 | 6/9/20 13:00 | 6/29/20 13:00 | V4_WEEK3_VAX2_S | 21 | 6/29/20 13:00 | SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay | 3 Weeks after Vaccination 1 | 3 | 10 |